Posted by Michael Wonder on 19 Sep 2022
Seagen announces Tukysa (tucatinib) in combination with trastuzumab granted priority review by FDA for previously treated HER2 positive metastatic colorectal cancer
19 September 2022 - FDA has set action date of 19 January 2023 .
Seagen today announced that the US FDA has accepted for priority review the supplemental new drug application seeking accelerated approval for Tukysa (tucatinib) in combination with trastuzumab for adult patients with HER2 positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease.
